Tag Archives | personalized medicine

Biotech Weakness but why Large Caps?…Updates

here Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but there was pronounced biotech weakness as well as in healthcare stocks one of the […]

Continue Reading 0

Biotechs Surge in August Best in Years: New Highs Hit for 2018…Updates

http://arc-theatre.com/company/theatre-links/ 9/4/18 Biotech Weakness -Profit Taking or Caution for September Swoon? 1 PM EDT FBT down 1.38%, IBB down 1.55%, XBI down 0.73% Biotech stocks were extremely weak as of mid-day trading. Large caps were unusually weak given that they should be less volatile: CELG down 3.55%, BIIB down 3.06%, ALXN down 2.66%, GILD down 2.55%, […]

Continue Reading 0

Biotech Snapshot: Healthcare Sector Remains Strong-Updates

buy Gabapentin 600 mg 8/24/18 After Close: Rally Continues with 10/11 Sectors Higher XLV finishes at all time high at $91.89 FED’s Powell Defends Gradual Interest Rate Policy despite Trump pressure Oil Surges 15 to $68.57 on supply concerns with Iran sanctions Major indices hit 52 week highs: S&P 500, Russell 2000, NASDAQ Composite IBB at $117.40 pushing toward 2018 FEB […]

Continue Reading 0

Biotechs Sell-Off Last Week: Growth Disappointing or Just Profit Taking? …Updates

Update 7/30 at close- –Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen:  ACAD down 4.08%, ALNY down 7.37%, BLUE down 4.46%, IMMU down 3.45%, NBIX down 7.68% IBB […]

Continue Reading 0

Biotechs Hold and Ignore Rocky Week of Global Politics- Big Earnings Upcoming…Updates CELG, BIIB, AZN, XBI

7/26 We will review all large cap earnings by Saturday 7/28. IBB flat to down over 5 days at $117.87; XBI down 3.2% over 5 days. Technicals do not look good. AstraZeneca (AZN) up 1.9%  to $38.15 on $1B new product growth. Stock is at 2018 highs. Biogen (BIIB) stock drops 10% to $344.75 as […]

Continue Reading 0

Biotech Bull Market: ETFs and Life Science Mutual Funds 2018 YTD

Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility  XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a level about midway between the highs and lows […]

Continue Reading 0

Rayno BioBeat #4 2018: ASCO Biotech Momentum Continues with M&A Theme…Updates 6/29

Momentous  Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170 level on news that a rival Company Galapagos (GLPG) […]

Continue Reading 0

Mid-Cap Biotech Watch List: Updated 6/12/18 After Huge ASCO Rally

  Updated 6/18 pre-market Biotech Update for Week Ending 6/15 A relatively quiet less volatile week with the bullish trend intact at “triple-top” with XBI at $97 level. However, NASDAQ weakness today could blunt run in biotechs. We probably had one of the best ASCO stock rallies on record in 2018 focusing on small and […]

Continue Reading 0

Mid-Cap Biotechs Lead the Market: Pre-ASCO Scoreboard…Updates 6/4/18

6/4/18…after close Update-2…IBB down 0.65%, XBI down 0.22%.  Momentum Waning Big Winners Today : BLUE, FMI, GHDX, IMMU, MRK It would appear that biotech stocks need to be bought prior to ASCO as has been then trend in the past i.e sell before the news. However there will be some clear cut winners after the Meeting. […]

Continue Reading 0

Financial and Political Crisis in Italy Disrupts Biotech Stock Momentum…Updates with rally today 5/30

Updates 5/30 Pre-ASCO Rally: XBI regains momentum to $94 level. IBB breaks through SMA 200 level to $108+. Many mid-caps from our watch list soaring-CRSP*, FMI, FOLD, LGND, LOXO, NKTR, SGEN, SRPT etc. *Note CRSP got whacked after hours down 13 points! The FDA has put the clinical trial for sickle cell treatment on hold. […]

Continue Reading 0